Mesoblast reaches target of 300 trial patients
- Mesoblast treated at least 300 patients in its pivotal Phase 3 trial for chronic low back pain.
- Following the announcement, the company's share price increased on the ASX.
- The trial aims to confirm durable pain reduction to support future regulatory approval filings.
Mesoblast (ASX:MSB) has treated 300 patients in a key clinical trial to validate a new low back pain therapy.
This phase 3 evaluation follows an earlier trial that demonstrated durable pain reduction from a single injection.
"Completing our target of treating at least 300 patients in the placebo-controlled pivotal back pain trial ensures the trial is well powered for success," said Mesoblast CEO Silviu Itescu.
The company stated that top-line results are expected in mid-2027 and could lead to peak annual revenues exceeding US$10 billion.
Following the announcement, the Mesoblast share price was up at $2.36.
The clinical milestone builds on a recent corporate update where the business received an official filing number from regulators.
The biotechnology firm also drew down US$50 million from a non-dilutive credit facility to support its ongoing commercial operations.
